Fatih Demirkan
Dokuz Eylül University
PathologyImmunologyIbrutinibDiabetes mellitusMedicine
What is this?
Publications 129
#1Mary Ann Anderson (WEHI: Walter and Eliza Hall Institute of Medical Research)H-Index: 12
#2Matthew S. Davids (Harvard University)H-Index: 33
Last. Tanya S. Rosenberg (AbbVie)
view all 13 authors...
Last. Bulent UndarH-Index: 11
view all 11 authors...
#1Fatih Demirkan (Dokuz Eylül University)H-Index: 12
#2Rafiye Ciftciler (Hacettepe University)H-Index: 1
Last. Yahya Buyukasik (Hacettepe University)H-Index: 18
view all 13 authors...
#1Alessandra TedeschiH-Index: 29
#2Richard GreilH-Index: 59
Last. John G. Gribben (QMUL: Queen Mary University of London)H-Index: 90
view all 20 authors...
#1Richard GreilH-Index: 59
#2Alessandra TedeschiH-Index: 29
Last. Fatih Demirkan (Dokuz Eylül University)H-Index: 12
view all 15 authors...
#1Silvia Maria Lavezzi (UNIPV: University of Pavia)H-Index: 1
#2Jan de Jong (Janssen Pharmaceutica)H-Index: 7
Last. Italo Poggesi (Janssen-Cilag)H-Index: 1
view all 19 authors...
Introduction In the HELIOS trial, bendamustine/rituximab (BR) plus ibrutinib (BR-I) improved disease outcomes versus BR plus placebo in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Here, we describe the pharmacokinetic (PK) observations, along with modeling to further explore the interaction between ibrutinib and rituximab.
#1Serdal Korkmaz (UHSA: University of Health Sciences Antigua)H-Index: 6
#2Serife Solmaz Medeni (UHSA: University of Health Sciences Antigua)H-Index: 1
Last. Fevzi Altuntas (Yıldırım Beyazıt University)H-Index: 16
view all 49 authors...
Abstract Therapeutic plasma exchange (TPE) is used to treat more than 60 diseases worldwide and has drawn growing interest. Little is known about the current situation of TPE activity in Turkey, so we developed a survey to obtain information about this timely topic. We collected data on TPE from 28 apheresis units throughout Turkey. We performed a total of 24,912 TPE procedures with 3203 patients over the past decade. Twenty years ago, the majority of procedures were performed for neurological a...
#1Graeme Fraser (McMaster University)H-Index: 12
#2Paula Cramer (University of Cologne)H-Index: 18
Last. Asher Chanan-Khan (Mayo Clinic)H-Index: 32
view all 28 authors...
We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without deletion 17p. Overall, 578 patients were randomized 1:1 to either ibrutinib (420 mg daily) or placebo, in combination with 6 cycles of BR, followed by ibrutinib or placebo alone. Median follow-up was 34.8 months (range: 0.1–45.8). Investigator-assessed median progre...
12 CitationsSource